Sunderland T - Search Results

1

Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.

Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T. Molchan SE, et al. Among authors: sunderland t. Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):215-26. doi: 10.1016/0165-0173(92)90017-g. Brain Res Brain Res Rev. 1992. PMID: 1467811 Clinical Trial.

2

TRH attenuates scopolamine-induced memory impairment in humans.

Molchan SE, Mellow AM, Lawlor BA, Weingartner HJ, Cohen RM, Cohen MR, Sunderland T. Molchan SE, et al. Among authors: sunderland t. Psychopharmacology (Berl). 1990;100(1):84-9. doi: 10.1007/BF02245795. Psychopharmacology (Berl). 1990. PMID: 2104988 Free article. Clinical Trial.

3

Psychobiological modeling of age-related memory changes.

Lister RG, Sunderland T, Weingartner HJ. Lister RG, et al. Among authors: sunderland t. Neurobiol Aging. 1988 Sep-Dec;9(5-6):505-6. doi: 10.1016/s0197-4580(88)80105-2. Neurobiol Aging. 1988. PMID: 3211258

4

Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans.

Molchan SE, Hill JL, Minichiello M, Vitiello B, Sunderland T. Molchan SE, et al. Among authors: sunderland t. Life Sci. 1994;54(13):933-8. doi: 10.1016/0024-3205(94)00629-6. Life Sci. 1994. PMID: 8139380 Clinical Trial.

5

The effects of scopolamine, lorazepam, and glycopyrrolate on classical conditioning of the human eyeblink response.

Bahro M, Schreurs BG, Sunderland T, Molchan SE. Bahro M, et al. Among authors: sunderland t. Psychopharmacology (Berl). 1995 Dec;122(4):395-400. doi: 10.1007/BF02246273. Psychopharmacology (Berl). 1995. PMID: 8657840 Clinical Trial.

6

Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans.

Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, Sunderland T. Vitiello B, et al. Among authors: sunderland t. Neuropsychopharmacology. 1997 Jan;16(1):15-24. doi: 10.1016/S0893-133X(96)00134-0. Neuropsychopharmacology. 1997. PMID: 8981385 Clinical Trial.

7

Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.

Martinez R, Molchan SE, Lawlor BA, Thompson K, Martinson H, Latham G, Weingartner H, Sunderland T. Martinez R, et al. Among authors: sunderland t. Biol Psychiatry. 1997 Jan 1;41(1):50-7. doi: 10.1016/0006-3223(95)00674-5. Biol Psychiatry. 1997. PMID: 8988795 Clinical Trial.

8

The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.

Molchan SE, Mellow AM, Hill JL, Weingartner H, Martinez R, Vitiello B, Sunderland T. Molchan SE, et al. Among authors: sunderland t. J Psychopharmacol. 1992 Jan;6(4):489-500. doi: 10.1177/026988119200600404. J Psychopharmacol. 1992. PMID: 22291397 Free article.

9

Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.

Sunderland T, Molchan SE, Little JT, Bahro M, Putnam KT, Weingartner H. Sunderland T, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 4:S23-6. Alzheimer Dis Assoc Disord. 1997. PMID: 9339269 Review.

10

A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.

Sunderland T, Molchan S, Lawlor B, Martinez R, Mellow A, Martinson H, Putnam K, Lalonde F. Sunderland T, et al. Int Psychogeriatr. 1992;4 Suppl 2:291-309. Int Psychogeriatr. 1992. PMID: 1288668 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters